Lipid peroxidation- and pyroptosis-induced tissue factor activation in pathogen-induced blood coagulation - tissue factor (TF), the primary initiator of the blood coagulation cascade, is carefully…

Active Grant Awarded

Award ID
R00HL166778
Recipient
Awarding agency
Obligated
$249,000

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 16% complete
Place of performance
Tyler, TX 75708, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded Grant R00HL166778 to The University Of Texas Health Science Center At Tyler on June 3, 2026, with $249,000 obligated under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds laboratory research into how lipid peroxidation and pyroptosis activate tissue factor in pathogen-induced blood coagulation. Aim 1 investigates the mechanisms by which the viral accessory protein ORF3A induces tissue factor activation through a phosphatidylserine-dependent pathway that requires TMEM16F, with emphasis on programmed cell death. Aim 2 uses chemical and genetic approaches to investigate whether tissue factor activation and intravascular coagulation activation induced by 4-hydroxy-2-nonenal (HNE), a reactive lipid peroxidation product, are mediated through programmed cell death. Performance runs from the June 3, 2026 award date through an ultimate completion date of April 30, 2029, at Tyler, Texas 75708. The assistance type is grant.

Description

Lipid peroxidation- and pyroptosis-induced tissue factor activation in pathogen-induced blood coagulation - tissue factor (TF), the primary initiator of the blood coagulation cascade, is carefully regulated to prevent aberrant coagulation activation. However, pathological conditions including bacterial and viral infection induce intravascular TF expression and lead to thrombosis. As TF-induced thrombosis is a major cause of acute myocardial infarction, ischemic stroke, and pulmonary embolism, improved understanding of the mechanisms of pathological TF activation may lead to new therapeutic targets. Pyroptosis, a form of inflammatory cell death, drives TF-mediated intravascular coagulation activation in bacterial sepsis. Emerging studies also implicate inflammasome activation in viral infections, but its role in TF activation is unknown. Our preliminary studies demonstrate that ORF3A, an accessory viral protein induce TF activation in a phosphatidylserine (PS)-dependent mechanism that requires TMEM16F, similar to PS-dependent TF activation in pyroptosis. In aim 1, my lab will investigate the underlying mechanisms that govern ORF3A-induced TF activation emphasizing the key roles of programmed-cell death. Lipid peroxidation and its highly reactive end products such as 4-hydroxy-2-nonenal (HNE) are involved in various forms of programmed cell death including pyroptosis. However, the role of HNE, the most stable and toxic reactive aldehyde produced during lipid peroxidation, in pyroptosis-associated TF and coagulation activation is not known. Our preliminary data showed that HNE induces PS-dependent TF activation in LPS-primed macrophages and causes intravascular coagulation activation in mice. However, the complete mechanism by which HNE induces PS externalization and TF activation is not known. In aim 2, my lab will use chemical and genetic approaches to investigate whether HNE-induced TF activation and intravascular coagulation activation is mediated through programmed cell death. Although lipid peroxidation plays a central role in cell death and coagulation activation in bacterial sepsis, a therapeutically targetable enzyme responsible for the unbridled lipid peroxidation and generation of pathological levels of reactive radicals such as HNE is not known. In aim 3, my lab will use genetically modified mice deficient in lipid peroxidation and HNE formation to investigate TF-dependent pathologic coagulation activation and thrombosis during sepsis. A successful completion of these studies will help delineate a common pathway involved in pathologic TF activation across varied pathogenic infections and will also help identify a specific therapeutically targetable enzyme to attenuate TF activation in disease.

Quick answers

Who received award R00HL166778?

R00HL166778 was awarded to The University Of Texas Health Science Center At Tyler by National Heart Lung and Blood Institute (National Institutes of Health) on June 3, 2026.

How much is award R00HL166778 worth?

$249,000 has been obligated on R00HL166778.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award